Lexaria Bioscience Corp (LXX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 08/31
| 05-2023 | 02-2023 | 11-2022 | 08-2022 | 05-2022 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 25 | 25 | 25 | 63 | 24 |
| Accounts receivable | -35 | 150 | -85 | -47 | 74 |
| Accounts payable and accrued liabilities | 834 | -52 | 90 | -6 | 40 |
| Other Working Capital | 480 | 25 | 353 | -465 | 171 |
| Other Operating Activity | -3,089 | -1,387 | -1,618 | -723 | -1,568 |
| Operating Cash Flow | $-1,786 | $-1,239 | $-1,234 | $-1,177 | $-1,259 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | -13 | -21 | N/A | N/A |
| Purchase Sale Intangibles | -34 | -19 | -14 | -50 | -31 |
| Other Investing Activity | -34 | -19 | -14 | 0 | -7 |
| Investing Cash Flow | $-34 | $-33 | $-35 | $-50 | $-38 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | 0 | 11 | -11 | -11 | -11 |
| Other Financing Activity | 1,711 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $1,711 | $11 | $-11 | $-11 | $-11 |
| Beginning Cash Position | 3,272 | 4,533 | 5,813 | 7,051 | 8,359 |
| End Cash Position | 3,164 | 3,272 | 4,533 | 5,813 | 7,051 |
| Net Cash Flow | $-108 | $-1,261 | $-1,280 | $-1,238 | $-1,308 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,786 | -1,239 | -1,234 | -1,177 | -1,259 |
| Capital Expenditure | -34 | -33 | -35 | -50 | N/A |
| Free Cash Flow | -1,820 | -1,272 | -1,269 | -1,227 | -1,259 |